- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Verekitug, Placebo
- Drug · Other
- Lead sponsor
- Upstream Bio Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 29
- States / cities
- Bakersfield, California • Encino, California • Lomita, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 278
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- End Stage Renal Disease
- Interventions
- fish oil, placebo
- Dietary Supplement
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Overweight or Obesity, Healthy
- Interventions
- Mango, Control
- Dietary Supplement
- Lead sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
- Industry
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- COPD
- Interventions
- QBM076, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Asthma, Pulmonary Disease, Chronic Obstructive
- Interventions
- Not listed
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stroke, Insulin Resistance, Sedentary Lifestyle
- Interventions
- Aerobic Exercise, Stretching
- Behavioral
- Lead sponsor
- Baltimore VA Medical Center
- Federal
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Inflammation, Atherosclerosis, Aortic Stiffness
- Interventions
- MRI carotid, APWV, Hydroxychloroquine, Matching Placebo
- Procedure · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Low-grade Chronic Inflammation, Intestinal Permeability, Type 2 Diabetes Mellitus, Cardiovascular Disease, Obesity
- Interventions
- Fructose-sweetened beverages, Glucose-sweetened beverages, High-fructose corn syrup-sweetened beverages
- Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Stroke, Fatigue, Chronic Stroke, Stroke Sequelae
- Interventions
- anodal transcranial direct current stimulation (a-tDCS), sham stimulation
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Anxiety, Anxiety Disorders, Anxiety Generalized, Anxiety Chronic, Inflammation, Inflammatory Response
- Interventions
- Cannabis (smoked flower, ingested edible)
- Drug
- Lead sponsor
- University of Colorado, Boulder
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer, Gallbladder Cancer
- Interventions
- Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Trauma Injury, Sepsis, Immunosuppression, Chronic Critical Illness
- Interventions
- Data Collection, Bone marrow collection and blood collection, Serial interviews to complete surveys and questionnaires, Telephone follow up call
- Other · Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 255 participants
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Meibomian Gland Dysfunction, Posterior Blepharitis
- Interventions
- Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sepsis
- Interventions
- Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP), Inspiratory Muscle Strength Training (IMST), SHAM Inspiratory Muscle Strength Training (IMST), Diaphragm thickness measurement, Blood and Urine samples
- Procedure · Drug · Device + 1 more
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Pulmonary Disease, Chronic Obstructive, Immunity, Innate, Inflammation, Bronchitis, Chronic, Toll-Like Receptors
- Interventions
- Not listed
- Lead sponsor
- VA Puget Sound Health Care System
- Federal
- Eligibility
- 50 Years to 89 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Asthma, Chronic Rhinosinusitis
- Interventions
- Endoscopic sinus surgery
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Healthy Lifestyle, Home Environment Related Disease, Cardiometabolic Disease, Systemic Inflammatory Response, Health Behavior, Dietary Habits, Physical Inactivity, Self Efficacy, Gut Microbiota, Diabetes Mellitus
- Interventions
- HomeStyles-China
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Psoriasis, Atherosclerotic Cardiovascular Disease, Obesity, Dyslipidemia, Cardiometabolic Diseases
- Interventions
- Niagen, Placebo
- Dietary Supplement · Other
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Asthma Acute, COPD Exacerbation Acute
- Interventions
- Rademikibart
- Drug
- Lead sponsor
- Connect Biopharm LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- End Stage Renal Disease (ESRD)
- Interventions
- AGE
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Septic Shock
- Interventions
- Not listed
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sarcopenia, Frailty, Aging
- Interventions
- MYMD-1 600MG, MYMD-1 750mg, MYMD-1 900mg, MYMD-1 1050mg, placebo 600mg, placebo 750mg, placebo 900mg, placebo 1050mg
- Drug
- Lead sponsor
- TNF Pharmaceuticals, Inc.
- Industry
- Eligibility
- 65 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Clearwater, Florida • Tampa, Florida • Baltimore, Maryland
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Interventions
- Nivolumab, Varlilumab
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (Stage 3)
- Interventions
- Low-dose Colchicine at 0.5mg daily, Usual Care
- Drug · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas